Cargando…
Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling
Immune-checkpoint therapy has failed to show significant benefit in glioblastoma (GBM) patients. Immunologic subtypes of GBM are necessary to identify patients who might benefit from immune-checkpoint therapy. This study reviewed 152 GBM samples from The Cancer Genome Atlas (TCGA) and 214 GBM sample...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202515/ https://www.ncbi.nlm.nih.gov/pubmed/32310827 http://dx.doi.org/10.18632/aging.103065 |